header logo image


Page 16«..10..15161718..»

Archive for the ‘Neuropathy’ Category

Close Association Between Diabetic Peripheral Neuropathy and Sarcopenia – Neurology Advisor

Friday, March 20th, 2020

There is a close association between sarcopenia and diabetic peripheral neuropathy (DPN), according to study results published in Diabetes Research and Clinical Practice.

Sarcopenia may lead to reduced exercise and increased risk for microvascular complications in patients with diabetes mellitus, including nephropathy and retinopathy. Because there is little information on the association between sarcopenia and DPN, the goal of the current cross-sectional study was to explore this association. In addition, a cohort study was carried out to investigate the changes in muscle mass and nerve conduction velocity.

The cross-sectional study included 1794 individuals (937 men; mean age, 60.22 years). Of these, 183 patients (98 men; mean age, 59.08 years) were enrolled in the follow-up study with a median follow-up of 2.7 years.

All patients underwent nerve conduction tests and muscle mass index was calculated using the following formula: appendicular skeletal muscle mass (ASM; in kg) divided by height squared (HT2; in m2 [ASM/HT2]). The composite z scores for the sensory nerve conduction velocity (SCV) and motor nerve conduction velocity (MCV) were calculated. The changes in ASM/HT2, SCV, and MCV were calculated from the measurements approximately 2 years apart and changes in skeletal muscle were classified into 3 groups: a decrease in ASM/HT2 of >3%, a minor change within 3%, or an increase of >3%.

In men, the multivariate regression analysis showed that muscle mass index was positively associated with the median (=0.928; P <.001), ulnar (=1.462; P <.001), peroneal (=1.059; P =.001), and tibial MCV (=0.839; P =.001) among the motor neurons; the median (=1.499; P <.001), ulnar (=0.837; P =.044), peroneal (=2.090; P =.002), and sural SCV (=1.257; P =.014) among the sensory neurons; and the composite z scores of MCV (=0.197; P <.001) and SCV (=0.3000; P <.001).

Receiver operating characteristic analysis indicated that the optimal cutoff point for ASM/HT2 that indicated DPN was 7.09 kg/m2 (area under the curve, 0.605; 95% CI, 0.569-0.642; sensitivity, 53.1%; specificity, 72.3%).

No significant correlations were found between ASM/HT2 and MCV, SCV and neuropathy score, and DPN and sarcopenia in women.

In the follow-up cohort study, there was a strong positive association between 2-year changes in skeletal muscle and nerve conduction velocity. During the follow-up period, nerve conduction velocity increased in terms of the partial motor and sensory velocities with an increase in the muscle mass in men with diabetes. However, similar to the findings in the cross-sectional analysis, this phenomenon was generally not observed in women with diabetes.

The researchers noted several limitations to the study, including possible selection bias as the study was performed in a hospital and included mainly middle-aged adults with nonsevere diabetes. As such, the findings may not be generalizable to older patients.

The assessment of muscle mass may have clinical implications in the prevention of DPN in men with diabetes, concluded the researchers.

Reference

Zhang Y, Shen X, He L, Zhao F, Yan S. Association of sarcopenia and muscle mass with both peripheral neuropathy and nerve function in patients with type 2 diabetes [published online February 25, 2020]. Diabetes Res Clin Pract. doi:10.1016/j.diabres.2020.108096

This article originally appeared on Endocrinology Advisor

View post:
Close Association Between Diabetic Peripheral Neuropathy and Sarcopenia - Neurology Advisor

Read More...

Six Benefits Of Acupuncture For Cancer Patients – Long Island Weekly News

Friday, March 20th, 2020

By Elizabeth Martin

More than 39 percent of the population will be diagnosed with cancer at some point in their life, so chances are, someone you know has had cancer. A 2019 study in JAMA Oncology found that acupuncture was significantly associated with lower pain levels for cancer patients. It seems that recently Eastern medicine, such as acupuncture, is integrating with Western medicine. The ongoing opioid crisis makes it more challenging to address cancer pain management, making acupuncture an alternative for pain.

One of the common side effects of chemotherapy is neuropathy, where nerve damage causes tingling, numbness and other sensations that can be extremely uncomfortable. This pain is often not treated or cant be treated with pain medication, but acupuncture proves to be a great alternative. Acupuncture and Chinese Medicine help open the body up and heal by promoting the flow of Qi (our vital energy). Acupuncture helps to bring circulation and blood flow to certain areas, helping the body to heal itself.

As a practitioner, I hear over and over that cancer patients are apprehensive about taking another medication for the side effects of another medication. But acupuncture is a noninvasive way to treat these side effects. I already mentioned that acupuncture helps with neuropathy because it stimulates blood flow to the damaged nerves. With nausea and loss of appetite, acupuncturists can open up channels that lead to the stomach meridian to help the body work more efficiently and improve the flow of energy to that area.

When someone has insomnia, its a sign that the brain is not shutting off. Acupuncture tells the neurotransmitters in the brain to calm down and helps to reprogram your bodys own circadian rhythm. When we are working on patients with insomnia, most of the time we choose to work on the heart meridians, because the heart calms the mind, and in traditional Chinese medicine we believe it is connected to the mind and spirit.

Often, schedules are packed with doctors appointments, but a visit to the acupuncturist is one to look forward to. I wanted my office to feel like home, so I purposely designed my practice to be that way, touching on the five elements of Chinese Medicine: wood, water, fire, earth, and metal and making it a tranquil, medical spa-like atmosphere. Doctors often look at their patients like a number, rushing to get them in and out of the door, but during an acupuncture appointment at our practice, we make a point to spend the time to get to know our patients and help to talk them through the emotions they may be going through during their cancer diagnosis and treatment.

Elizabeth Martin

The theory is that acupuncture is compared to going for a runincreasing circulation, draining the lymph nodes, and releasing toxins. Whenever you get acupuncture, it releases neurotransmitters in the brain like serotonin and epinephrine, which helps boost energy levels and improve mood. At the practice we also use acupuncture to help treat allergies, as it goes back to my earlier point about opening the flow of Qi.

With the treatments and appointments that many cancer patients are already going to, they can often be afraid and apprehensive to try acupuncture while in treatment. But in fact, this is the best time to go. We often hear from our cancer patients that they felt overwhelmed with adding another appointment, but after coming to acupuncture they felt more relaxed, had less pain, and felt calmer after undergoing regular acupuncture treatments. Often the patients that were skeptical of acupuncture would take a break and very often when stopping acupuncture regularly, it caused their pain to return.

Acupuncture is only one pillar of Chinese Medicine, but other modalities include manual therapy, Chinese herbal medicine, and meditation practices like Qi gong. A recent meta-analysis in patients with cancer and insomnia showed that yoga, meditation, hypnosis, mindfulness-based stress reduction, and qi gong have a moderate effect on the improvement of sleep quality for up to three months. At my practice, we also do sound healing classes, which has been a great way to start meditation and can help reduce stress. This practice uses vibrations (vocal or instrumental-like gongs, Tibetan singing bowls and tuning forks) in order to relax your mind and body.

Elizabeth Martin is a board-certified licensed acupuncturist. She is the owner of Hands On Acupuncture and Massage Therapy PC on Long Island. Visit http://www.handsonacupuncture.com to learn more.

See the rest here:
Six Benefits Of Acupuncture For Cancer Patients - Long Island Weekly News

Read More...

Diabetic Peripheral Neuropathy Treatment Market Industry Production and Demand, Competition News and Trends Forecasts to 2024 – Jewish Life News

Friday, March 20th, 2020

With having published myriads of reports, Diabetic Peripheral Neuropathy Treatment Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, Diabetic Peripheral Neuropathy Treatment Market Research serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Diabetic Peripheral Neuropathy Treatment market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Diabetic Peripheral Neuropathy Treatment market.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2251608&source=atm

The Diabetic Peripheral Neuropathy Treatment market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

The following manufacturers are covered:Achelios Therapeutics IncCelgene CorpCommence Bio IncGrunenthal GmbHImmune Pharmaceuticals IncKPI Therapeutics IncMedifron DBT Co LtdMitsubishi Tanabe Pharma CorpNovaremed LtdReata Pharmaceuticals IncRelief Therapeutics Holding AGViroMed Co Ltd

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeAntimunocelASP-8477BNV-222CapsaicinCBX-129801Others

Segment by ApplicationHospitalClinicOthers

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2251608&source=atm

What does the Diabetic Peripheral Neuropathy Treatment market report contain?

Readers can get the answers of the following questions while going through the Diabetic Peripheral Neuropathy Treatment market report:

And many more

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2251608&licType=S&source=atm

For More Information Kindly Contact:

ResearchMoz.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Read more:
Diabetic Peripheral Neuropathy Treatment Market Industry Production and Demand, Competition News and Trends Forecasts to 2024 - Jewish Life News

Read More...

Diabetic Neuropathy Market Application 2020 Industry Trends, Global Analysis, Business Growth & Demand, Top 5 Leading Players, Sectors &…

Friday, March 20th, 2020

Diabetic Neuropathy Market Research Report 2020, is mostly driven by the improved taking on of Diabetic Neuropathy across small and medium-sized enterprises. Worldwide Diabetic Neuropathy Market quantifying the talk on those players at the interval. The report figures the limits and strong points of the players. To begin with the Diabetic Neuropathy Market report which covers market characteristics, industry structure and comitative landscape, the problems, desire concepts, along with business strategies market effectiveness.

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

About Diabetic Neuropathy Market Report

This research report categorizes the global Diabetic Neuropathy Market by players/brands, region, type and application. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

Market Competition by Top Key Players/Manufacturers:

Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/213

Diabetic Neuropathy Market Dynamics in the world mainly, the worldwide 2020-2026 Diabetic Neuropathy Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Major Highlights of the Diabetic Neuropathy Market Report:

Diabetic Neuropathy Market Overview, Market shares and strategies of key players, Sales Market Forecast, Manufacturing Analysis of Diabetic Neuropathy, Market Driving Factor Analysis of Diabetic Neuropathy, Market Competition Status by Major Manufacturers, Upstream and Downstream Market Analysis of Diabetic Neuropathy, and Cost and Gross Margin Analysis of Diabetic Neuropathy.

Why This Report is Useful? It helps:

1. The report will include the qualitative and quantitative analysis with Diabetic Neuropathy Market estimation and compound annual growth rate (CAGR) between 2020 and 20262. Assess the Diabetic Neuropathy production processes, major issues, and solutions to mitigate the development risk.3. Comprehensive analysis of market dynamics including factors and opportunities of the global Diabetic Neuropathy Market will be provided in the report4. Insights from this report will allow marketers and management authorities of companies to make informed decisions with respect to their future product launch, technology upgrades, market expansion, and marketing tactics.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

Further in the report, the Diabetic Neuropathy market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and regions are also included. The Diabetic Neuropathy industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

In this study, the years considered to estimate the market size of 2020-2026 Diabetic Neuropathy Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2020Forecast Year 2020 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Visit link:
Diabetic Neuropathy Market Application 2020 Industry Trends, Global Analysis, Business Growth & Demand, Top 5 Leading Players, Sectors &...

Read More...

Kannalife, Inc. Receives Seventh Patent by Extending Patent Family to Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders…

Friday, March 20th, 2020

DOYLESTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (KLFE), a biopharmaceutical med-chem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued Australian Patent AU2015204609B2 (the Patent) specific to Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy. This patent grant marks the seventh patent that Kannalife has received to date on a worldwide basis.

Under the Patent, Kannalife will further explore the application and potential of new molecular entities (NMEs) across epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson's disease, Alzheimer's, Huntington's disease, and amyotrophic lateral sclerosis (ALS).

Australias pharma market is expected to reach $32.1 billion in 2020, according to data from research and consulting firm GlobalData.1

"We are pleased to see our IP estate recognized in Australia as novel and proprietary. We see this as an important first step towards commercializing our lead drug candidate KLS-13019 in that market in thefuture," said Dean Petkanas, CEO of Kannalife.

KLS-13019 leads Kannalifes intellectual property estate of novel, monotherapeutic molecules (KLS Family), which are capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress, and neurodegenerative disorders.

Of the seven patents issued to Kannalife on this technology, two are U.S. patents and five are foreign patents claiming priority to Kannalifes original 2014 U.S. filing date through international application PCT/US2015/010827, which was published as WO2015/106108A2 titled, "Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy (the PCT Patent). The seven patents consist of AU2015204609B2, and the following six patents:

The Company recently completed a STTR phase 1 study funded by a grant from the National Institutes of Healths National Institute on Drug Abuse. The study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative monotherapeutic in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN).

Kannalife also has national phase patent applications based on the PCT Patent application pending in Canada, Brazil and India.

About KLS-13019KLS-13019 is Kannalifes leading proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical med-chem company focused on the development of proprietary and patented novel monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Story continues

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

References1. Drug Development & Deliver. Australias Pharma Sector to Grow to $32.1 Billionhttps://drug-dev.com/australias-pharma-sector-to-grow-to-32-1-billion/

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View post:
Kannalife, Inc. Receives Seventh Patent by Extending Patent Family to Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders...

Read More...

The Global Diabetic Neuropathy Treatment Market Anticipated to exhibit a CAGR 4.9% during Forecast Period 2018-2025. – Galus Australis

Monday, March 16th, 2020

The global Diabetic Neuropathy Treatment market research report initiates a comprehensive analysis of the global Diabetic Neuropathy Treatment market. It offers an in-depth analysis of the rate of development of the market in the estimated time period. Offering a brief outline, the report explores the influencing factors and size of the global Diabetic Neuropathy Treatment market in the estimated period. It also covers the major leading factors restraining the expansion of the global Diabetic Neuropathy Treatment market. The global Diabetic Neuropathy Treatment market research report emphasizes commanding players in the market linked with their market shares.

Get Access to the FREE sample report: https://digitsnmarkets.com/sample/4316-diabetic-neuropathy-treatment-market

The report offers helpful data that discloses the foremost players in the Diabetic Neuropathy Treatment market it also discusses the revenue division, business general idea, and product contributions of the key players in the market. The research study also analyzes the growth of the well-known market performers with the help of SWOT analysis. In addition, while evaluating the growth of main market players, the research report covers their recent business developments. Furthermore, various products and segments

Table of Content

Chapter 1: IntroductionChapter 2: Executive SummaryChapter 3: Market OverviewChapter 4: Diabetic Neuropathy Treatment Market, By TypeChapter 5: Diabetic Neuropathy Treatment Market, By DisorderChapter 6: Diabetic Neuropathy Treatment Market, By ApplicationChapter 7: Diabetic Neuropathy Treatment Market, By RegionChapter 8: Competition Landscape

The global Diabetic Neuropathy Treatment market is bifurcated on the basis various segments. The development of each segment is evaluated along with their predicted growth in the future. Reliable data and statistics are collected from the regulatory authorities to calculate the growth of various segments of the market. Additionally, the global Diabetic Neuropathy Treatment market is also divided on the basis of various regions such as the North America, and Europe, Asia Pacific, Latin America, and Middle East & Africa.

How This Report On Diabetic Neuropathy Treatment Market Can Help You?

About Digits N Markets:

Digits N Markets has a vast repository of latest market research reports on trending topics, niche company profiles, market size and other relevant data released by renowned publishers. We have access to the database related to niche markets and trending topics in various industries. We also update the data regularly to provide recent statistics to the client. Recent data and reports will be featured on our websites and clients will be able to access the same. Our clients will be able to benefit from qualitative & quantitative insights in the report which will support them in taking concrete business decisions.

Contact Us:

Digits N Markets410 E Santa Clara Street, Unit #762San Jose, CA 95113Phone :+1 408-622-0123Email: [emailprotected]Website:- http://www.digitsnmarkets.com

See more here:
The Global Diabetic Neuropathy Treatment Market Anticipated to exhibit a CAGR 4.9% during Forecast Period 2018-2025. - Galus Australis

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Current Analysis and Estimated Forecast to 2026 | Achelios Therapeutics Inc,…

Monday, March 16th, 2020

Index Markets Researchoffers a latest published report on the GlobalChemotherapy Induced Peripheral Neuropathy TreatmentMarket that contains data regarding CAGR forecasts and key parameters such as yearly market growth in order to have complete statistics about the future of the market worldwide. It also helps in showing the extensive scope that will open up for the market. The research encompasses various factors about the Chemotherapy Induced Peripheral Neuropathy Treatment market such as its popularity in the global market, segmentation, current trends that are being followed, technological advancements, and future forecasts. The report provides key statistics on market trends and advancements that can help the businesses operating in the industry to understand the market and strategize for their expansion accordingly.

Request for Sample Report @https://www.indexmarketsresearch.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-market-2/407461/#requestforsample

Global Chemotherapy Induced Peripheral Neuropathy Treatment market 2020-2026: Competitive AnalysisWe provide a detailed analysis of key players operating in the global Chemotherapy Induced Peripheral Neuropathy Treatment market, including key players such asAchelios Therapeutics Inc, Advinus Therapeutics Ltd, Apollo Endosurgery Inc, Aptinyx Inc, Asahi Kasei Pharma Corp, Can-Fite BioPharma Ltd, Celgene Corp, DermaXon LLC, Eisai, Immune Pharmaceuticals Inc, INSYS Therapeutics Inc, Kineta Inc, KPI Therapeutics Inc, Krenitsky Pharmaceuticals Inc, MAKScientific LLC, Metys Pharmaceuticals AG, Midatech Pharma US Inc, Mundipharma International Ltd, Nemus Bioscience Inc, Neurocentrx Pharma Ltd, Panacea Pharmaceuticals Inc, PeriphaGen Inc, PharmatrophiX Inc, PledPharma AB, Sova Pharmaceuticals Inc, Virobay Inc, WEX Pharmaceuticals Inc.

This comprehensive Chemotherapy Induced Peripheral Neuropathy Treatment Market research report includes a brief summary of the market considering the current and future scenarios. The report further illustrates detailed breakdown of the market region-wise and categorizes it at various levels. The report provides rival insights of key players in the business vertical followed by an overview of their different portfolios and growth strategies. An elaborative analysis of business vertical delivers a brief overview of the various segments that encompass this industry landscape. A detailed evaluation of the current market status has been described in this report study. Thorough analysis on the varied aspects like opportunities and restraints are provided in this report.

The Report can be Segmented as:Product Type Segmentation :APX-3330, BR-297, Cannabidiol, Dimiracetam, OthersIndustry Segmentation:Clinic, Hospital, Others

Region Coverage (Regional Production, Demand & Forecast by Countries etc.):* North America (U.S., Canada, Mexico)* Europe (Germany, U.K., France, Italy, Russia, Spain etc.)* Asia-Pacific (China, India, Japan, Southeast Asia etc.)* South America (Brazil, Argentina etc.)* Middle East & Africa (Saudi Arabia, South Africa etc.)

The report reviews the competitive landscape scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies. The research report is collated on the idea of historic and forecast data that will help the emerging market segments in making major business decisions. The Chemotherapy Induced Peripheral Neuropathy Treatment Market is one among the fastest-growing market and further explains the trajectory this market will absorb the forecast years. The main objective of this Chemotherapy Induced Peripheral Neuropathy Treatment research report is to define the size of the different segments and the geographies as well as to forecast the trends that are likely to gain traction in the following couple of years.

Reasons to Buy:* Obtain the most up to date information available on the Chemotherapy Induced Peripheral Neuropathy Treatment projects globally.* Identify growth segments and opportunities in the industry.* Facilitate decision-making on the basis of strong historical and outlook of Chemotherapy Induced Peripheral Neuropathy Treatment data.* Develop business strategies with the help of specific insights about the planned and announced Chemotherapy Induced Peripheral Neuropathy Treatment projects globally.* Keep abreast of key new-build Chemotherapy Induced Peripheral Neuropathy Treatment projects globally.* Assess your competitors planned and Chemotherapy Induced Peripheral Neuropathy Treatment projects and capacities.

The report highlights the most recent market trends that are affecting the Chemotherapy Induced Peripheral Neuropathy Treatment market growth. It investigates the existing scenario of the global market, which takes into account several market dynamics with the combination of best industry insight, practical solutions, talent solutions and latest technology. To prepare this report, our analysts have used advanced primary and secondary research techniques and tools. The market contains the ability to become one of the most lucrative industries as factors related to this market such as divestments, launches, enhancements, partnerships, mergers, acquisitions, and other strategic initiatives by players in the Chemotherapy Induced Peripheral Neuropathy Treatment market.

Key Stakeholders1. Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers2. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors/Traders/Wholesalers3. Chemotherapy Induced Peripheral Neuropathy Treatment Subcomponent Manufacturers4. Industry Association5. Downstream Vendors

The Chemotherapy Induced Peripheral Neuropathy Treatment market report also mentions the consumption and supply as well as the export and import figures of the industry during the forecast period starting from 2015 to 2020. In addition, aspects such as the cost, revenue, gross margins, and price of Chemotherapy Induced Peripheral Neuropathy Treatment in the forecast horizon from 2015 to 2020 in terms of regions and countries. The forecast presented in the report evaluates the actual cost of the different types of Chemotherapy Induced Peripheral Neuropathy Treatment and the cost as per brands in the global Chemotherapy Induced Peripheral Neuropathy Treatment market over the forecast period. The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Read Detailed Index Report @https://www.indexmarketsresearch.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-market-2/407461/

The report provides key data points which includes important results and insights from our monitoring and analysis of the market for Chemotherapy Induced Peripheral Neuropathy Treatment industry. The report gives an analysis of important market events at regional and global levels. The report sheds light on current market trends, market dynamics, key opportunities and major challenges in the industry.

Request customize If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @sales@indexmarketsresearch.com

Read the original post:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Current Analysis and Estimated Forecast to 2026 | Achelios Therapeutics Inc,...

Read More...

‘He’s an inmate’: Anguish mounts over virus-hit nursing home – RiverBender.com

Monday, March 16th, 2020

AP Mar 14, 2020 2 days ago

In this March 12, 2020, photo, Steve Sedlacek, right looks at his father, Chuck Sedlacek, back left, through reflections in the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek's brother Scott said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

Flowers and other memorials are viewed Friday, March 13, 2020, near a sign at the entrance to the Life Care Center in Kirkland, Wash., near Seattle, which has been at the center of the coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, Scott Sedlacek poses for a photo while holding a photo of his father, Chuck, outside Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek who also has tested positive for the virus said he and his siblings have barely spoken to their father, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

A nurse works in the room of Chuck Sedlacek who has tested positive for the COVID-19 coronavirus Friday, March 13, 2020, as seen through the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek's son Scott Sedlacek said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020 photo, Scott Sedlacek becomes animated as he holds a picture of his father, Chuck, and talks to reporters outside Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek who also has tested positive for the virus said he and his siblings have barely spoken to their father who lives inside the center, and in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, Scott Sedlacek, left, who has tested positive for the COVID-19 coronavirus, listens as Tim Killian, right, a spokesman for Life Care Center in Kirkland, Wash., answers one of Sedlacek's questions during Killian's daily press briefing. Sedlacek's father, Chuck, who also has tested positive, lives in the facility, which has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek said he and his siblings have barely spoken to their father, who has blindness and neuropathy, and difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, a person is loaded into an ambulance at Life Care Center in Kirkland, Wash., which has been at the center of the COVID-19 coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 6, 2020, photo, Su Wilson, left, takes a photo with a worker at Life Care Center in Kirkland, Wash., after handing off flowers to give to her mother, June Liu, who lives at the facility, which has been at the center of the COVID-19 coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 6, 2020, photo, Su Wilson, front left, smiles after giving a worker at Life Care Center in Kirkland, Wash., flowers to give to her mother, June Liu, who lives at the facility, which has been at the center of the COVID-19 coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 11, 2020, photo, Scott Sedlacek, right, who has tested positive for the COVID-19 coronavirus, wears a mask as he stands near reporters and listens to a spokesman for Life Care Center in Kirkland, Wash., during a daily press briefing. Sedlacek's father, Chuck, who also has tested positive, lives in the facility, which has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek said he and his siblings have barely spoken to their father, who has blindness and neuropathy, and difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

A nurse wearing a mask walks past the room of Chuck Sedlacek who has tested positive for the COVID-19 coronavirus Friday, March 13, 2020, as seen through the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek's son Scott Sedlacek said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, family members of Chuck Sedlacek, left, look at him through reflections in the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek's son Scott said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 11, 2020, photo, Scott Sedlacek, left, who has tested positive for the coronavirus, wears a mask as he stands near reporters and listens to Tim Killian, right, a spokesman for Life Care Center in Kirkland, Wash., during Killian's daily briefing. Sedlacek's father Chuck, who also has tested positive, lives in the facility, which has been at the center of the coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, Scott Sedlacek becomes animated as talks to reporters outside Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek who also has tested positive for the virus said he and his siblings have barely spoken to their father who lives inside the center, and in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, family members of Chuck Sedlacek wave and greet him through reflections in the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek's son Scott said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, Scott Sedlacek poses for a photo while holding a picture of his father, Chuck, outside Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek who also has tested positive for the virus said he and his siblings have barely spoken to their father, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 11, 2020, photo, Scott Sedlacek, left, who has tested positive for the coronavirus, wears a mask as he stands with his brother Steve outside the Life Care Center in Kirkland, Wash. Their father Chuck, who also has tested positive, lives in the facility, which has been at the center of the coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

KIRKLAND, Wash. (AP) Desperate to talk to their dad, Scott Sedlacek and his brother, Steve, stood outside his open nursing home window and shouted. They could barely hear his weak replies, but one came through clearly.

I feel like (expletive), the 86-year-old told them.

Chuck Sedlacek arrived at the Life Care Center of Kirkland three weeks ago for physical therapy, just before the suburban nursing home became the epicenter of the nation's worst coronavirus outbreak.

Now he's in worse shape than before.

Hes in isolation after contracting the virus, but his symptoms haven't progressed enough to warrant moving him to a hospital. He came seeking rehab for a broken ankle and banged-up knee after a fall, but he hasn't gotten out of bed in two weeks. Though he previously lived independently in a senior community where he could walk the halls and visit old friends, hes now losing his mobility from lack of exercise.

His five children have hardly spoken with him because his near blindness and neuropathy in his hands make it tough for him to use a phone. And, they say, the overwhelmed Life Care staff has given him just two sponge baths since he arrived.

Hes an inmate as much as he is a patient, said Scott Sedlacek, 64, who also caught the virus. We all love and really care about our dad, and we are absolutely scared. Loneliness kills a lot of people, too. We think this is a license for death.

The Sedlaceks experience is a grim tale of what residents and their loved ones face as the coronavirus spreads around the country and enters other long-term care facilities. While most people recover from the virus and many have mild symptoms, elderly residents are especially at risk.

The virus has been confirmed in at least 11 nursing homes or senior apartments in western Washington. A cluster has also emerged at a veterans home in Lebanon, Oregon, where eight cases were confirmed in recent days.

Nursing homes around the country which are frequently cited for infection control problems are on high alert for coronavirus, boosting their cleaning regimens and clamping down on visitors.

The families of the remaining Life Care residents have reason to be terrified. More than two dozen coronavirus deaths have been linked to the facility, and more than half of those inside have tested positive.

The residents remain in a purgatory. They are mostly restricted to their rooms with no visitors. Roommates or neighbors across the hall have vanished without explanation. Some people are confused about whats going on.

The families, meanwhile, say their anguish has been compounded by mixed messages and a lack of information.

The nurses have told the Sedlaceks they check their fathers temperature every four to eight hours, less often than the two hours promised by administrators. That's troubling, since the virus seems able to cause fevers to spike drastically in a short period. The family has no idea how or when theyll be able to transfer their father out of the center if he recovers from the virus.

Families also question why, long after the outbreak began in China, the U.S. health system was so ill-prepared to test for coronavirus that the facility was still admitting new patients, including Chuck Sedlacek, even after the first resident had been sent to the hospital with flu-like symptoms.

Life Care said there was no reason to think the cornavirus was present until it received news Feb. 29 that a resident had tested positive. Administrators said remaining workers one-third are out with virus symptoms are doing what they can to care for residents.

All I can say is the nurses share your frustration, spokesman Tim Killian told the Sedlaceks when they questioned him during a media availability outside the nursing home this week. We have diminished capability to take care of all the patients in the exact manner they need. ... We do need more help.

The inability to comfort confused parents has been especially painful.

June Lius family used to pick her up several times a week for home-cooked Taiwanese meals and church services. The 93-year-old, who doesnt speak English, has lived at Life Care for two years since a small stroke.

During a flu outbreak there last year, she was able to leave the facility to stay with her daughter, Su Wilson. But now shes stuck at the facility after developing a cough two weeks ago and testing positive for the virus. She doesn't understand why no one is coming to visit her and why she cant go stay with her family.

I think shes very, very depressed, not knowing whats going on, Wilson said. This is sad for a lot of families and for us. The staff are trying to do their best, but are you caring for their mental health, or is it just Isolation! Isolation! Check vitals! IV!?

Wilson has now taken to leaving homemade soup outside the nursing home for staff to bring inside to her mom.

There is hope that outbreaks at other nursing homes might be less severe as they adopt restrictions and learn from Life Cares experience.

For example, at the senior living community where Chuck Sedlacek typically lives, Emerald Heights in Redmond, a staff member at a skilled nursing facility developed symptoms early this month and immediately began staying home before a test confirmed the disease. Eleven residents deemed at risk were quickly isolated and tested; only one was positive.

Meanwhile, though, a resident of the separate independent living community has been confirmed to have the disease and is now in self-isolation.

Despite our advanced planning, were having to run very, very fast to stay ahead of this virus, said Kris Egskov, Aegis Living president, after a resident at Aegis Marymoor in Redmond, Washington, tested positive. We are preparing for the long-haul and accept that this may in fact be an entirely new paradigm in which to protect our residents.

Scott Sedlacek visited his dad four times before Life Care was locked down to visitors on Feb. 29. No one inside was even wearing face masks, he said.

On March 1, the sons joints began to ache. He spent two days trying to get tested for COVID-19, asking doctors as well as public health officials. Even though hed spent time at Life Care, the center of the worst U.S. outbreak, he couldnt obtain a test until after his fever spiked, he had trouble breathing and his wife brought him to a hospital emergency room, which cleared him of the flu and other illnesses.

He felt fine again within 12 hours of being treated with a bronchial nebulizer, and he quarantined himself until last Wednesday, when he cut the period short so he could visit his dad through the hospital window. He wore a yellow face mask as he yelled to him.

This is supposed to be my last day of quarantine, but being with my dad is way more important, Sedlacek said that night. Hes in there and hes lonely. The big thing we wanted to convey to him was, Were here for you, we love you and we want you to get better we just cant be in there with you.

___

Johnson reported from Seattle.

___

The Associated Press receives support for health and science coverage from the Howard Hughes Medical Institutes Department of Science Education. The AP is solely responsible for all content.

___

Follow AP coverage of the virus outbreak at https://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak

Subscribe for FREE today.

We want to hear from you. Provide your thoughts and comments below.

The rest is here:
'He's an inmate': Anguish mounts over virus-hit nursing home - RiverBender.com

Read More...

Yorkshire Ripper Peter Sutcliffe struck down with condition that leaves him uncontrollably shaking – The Sun

Monday, March 16th, 2020

THE Yorkshire Ripper is suffering from a condition that leaves him with uncontrollable shaking.

Ailing Peter Sutcliffe, 73, has been diagnosed with diabetic neuropathy, causing tremors in his limbs.

2

It means the serial killer often shakes so badly he struggles to eat and to look after himself.

The progressive illness which is linked to overweight Sutcliffes diabetes is caused by high blood sugar levels and can result in nerve damage, numbness, pain and cramps.

In severe cases, sufferers cannot feel their limbs due to nerve damage. And it can lead to limbs, particularly feet, having to be amputated.

The Ripper, being held at Category A Frankland Prison, County Durham, is in poor general health and is given a daily cocktail of pills.

He has previously suffered a heart attack and angina.

Sutcliffe, who killed 13 women and attempted to murder seven more between 1975 and 1980, is waiting for an NHS operation to reduce the size of his prostate.

STAY HOMELondoners told to stay home as capital is worst hit by coronavirus

END THE EVENTSBoris Johnson says mass gatherings 'no longer supported' by government

Exclusive

CASHING INCoronavirus ghouls try to cash in on death with FAKE fundraising page for victim

Breaking

NEIGHBOUR BLOODBATHTwo women stabbed to death as man arrested for 'double murder'

TRAIL BLAZERWho is Jennifer Hosten and when did she win Miss World?

IN THE DOCKAlex Salmond alleged victim claims it was like 'wrestling an octopus'

He is also losing his eyesight, which medics have fought to save.

A source told The Sun on Sunday: Sutcliffe does not look a well man and his shakes are really noticeable. It is really bothering him.

This condition is one of the worst things you can get if youre diabetic particularly if youre fairly old and overweight.

2

View original post here:
Yorkshire Ripper Peter Sutcliffe struck down with condition that leaves him uncontrollably shaking - The Sun

Read More...

Intraoperative Neuromonitoring Market in the US 2020-2024 | Evolving Opportunities with Accurate Neuromonitoring LLC and Cadwell Industries Inc. |…

Monday, March 16th, 2020

The intraoperative neuromonitoring market in US is poised to grow by USD 955.33 million during 2020-2024, progressing at a CAGR of over 10% during the forecast period. Request free sample pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005573/en/

Technavio has announced its latest US research report titled Intraoperative Neuromonitoring Market in US 2020-2024 (Graphic: Business Wire)

Read the 120-page report with TOC on "Intraoperative Neuromonitoring Market In US Analysis Report by Type (Insourced IONM and Outsourced IONM), Application (Orthopedic and neurosurgeries, Cardiovascular surgeries, ENT surgeries, and Other surgeries), Methodology (Evoked potential (EP) monitoring, Electroencephalogram (EEG), and Electromyography (EMG), End-user (Hospitals, Ambulatory surgical centers (ASG), and Other end-users), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/intraoperative-neuromonitoring-market-in-us-industry-analysis

The market is driven by the increasing number of surgeries that require IONM. In addition, the rising adoption of remote IONM is anticipated to boost the growth of the intraoperative neuromonitoring market in the US.

The number of high-risk surgeries such as cardiovascular procedure, musculoskeletal, and spinal is increasing. Many people in the US, suffering from this condition experience severe long-term pain and disabilities. In addition, patients suffering from cervical or neck pain and lumbar or low back pain require medical attention. IONM are extensively used by surgeons because these medical conditions are often associated with neurological complications. For instance, surgeons use IONM while performing spine surgery because it allows the early identification of electrophysiologic changes. It is also used to identify hemodynamic and other abnormalities. Thus, the increasing number of surgeries that require IONM is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Intraoperative Neuromonitoring Companies in the US:

Accurate Neuromonitoring LLC

Accurate Neuromonitoring LLC operates the business under the Services segment. The company offers various services including motor strip mapping, cranial nerve monitoring, pedicle screw stimulations, and more. It also offers intraoperative neuromonitoring for performing neuro-surgical and other procedures.

Cadwell Industries Inc.

Cadwell Industries Inc. offers products through the following business units: EEG, EMG, IONM, Sleep, CADLINK, and Electrodes and accessories. The company offers Cascade IOMAX, Cascade PRO, Arc Alterna, and Arc Essentia.

Computational Diagnostics Inc.

Computational Diagnostics Inc. operates under various business segments, namely NeuroNet and Services. The company offers NeuroNet VII, NN600, and NN650. NN650 is a durable and easy to use IOM system, whereas, NN600 is a portable multi-modality capable system.

IntraNerve Neuroscience Holdings LC

IntraNerve Neuroscience Holdings LC offers products through the Services business segment. The company offers neuroscience services such as remote professional interpretation services, neurotelemetry/cEEG services, and intraoperative neuromonitoring services.

Medtronic Plc

Medtronic Plc offers products through the following business segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The company offers NIM-RESPONSE 3.0, BIS Complete 2-Channel Monitor, BIS Complete 4-Channel Monitor, and NIM-Neuro 3.0.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Intraoperative Neuromonitoring Market in US: Type Outlook (Revenue, USD Billion, 2020-2024)

Intraoperative Neuromonitoring Market in US: Application Outlook (Revenue, USD Billion, 2020-2024)

Intraoperative Neuromonitoring Market in US: Methodology Outlook (Revenue, USD Billion, 2020-2024)

Intraoperative Neuromonitoring Market in US: End-user Outlook (Revenue, USD Billion, 2020-2024)

Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care Include:

Neurodiagnostic and Monitoring Devices Market Global Neurodiagnostic and Monitoring Devices Market by product (electroencephalograph (EEG) devices, intracranial pressure (ICP) devices, electromyography (EMG) devices, and others) and geography (Asia, Europe, North America, and ROW).

Diabetic Neuropathy Drugs Market Global Diabetic Neuropathy Drugs Market by action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005573/en/

Read more:
Intraoperative Neuromonitoring Market in the US 2020-2024 | Evolving Opportunities with Accurate Neuromonitoring LLC and Cadwell Industries Inc. |...

Read More...

Promising Clinical Activity for RT Plus ICIs in Locally Advanced Head and Neck Cancers – Cancer Therapy Advisor

Friday, March 13th, 2020

Promising results were observed in a small, single-arm, phase 2 studyevaluating the efficacy and safety of the programmed cell death-1 (PD-1)inhibitor, pembrolizumab, plus radiation therapy (RT) in patients with locallyadvanced head and neck cancers who were ineligible to receive cisplatin-basedchemoradiation therapy. These findings were presented during the 2020Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Arizona.

Cisplatin-based chemoradiation therapyis considered a standard of care for the treatment of locally advanced squamouscell carcinoma of the head and neck (LA-HNSCC), with cisplatin acting as both achemotherapeutic agent and a sensitizer to ionizing radiation. However, it isnot uncommon for patients to have contraindications to the receipt of cisplatintherapy, thereby necessitating selection of another radiosensitizer forconcomitant use with RT.

The choice of pembrolizumab as asubstitute for cisplatin in the setting of LA-HNSCC was based, in part, onprevious studies showing that radiation elicitsand promotes tumor-directed immune-stimulation, which may potentiate antiPD-1therapy, the study authors commented.

None of the 29 adult patients enrolled in this study (ClinicalTrials.gov Identifier: NCT02609503) had undergone prior curative treatment for LA-HNSCC, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 was a study inclusion criterion. Pembrolizumab was administered concurrently with RT every 3 weeks for 3 cycles followed by 3 cycles of pembrolizumab. The primary study endpoint was progression-free survival (PFS), with overall survival (OS) and safety included as secondary study endpoints.

Twenty patients hadcancers of the tongue or tonsil, with a variety of other sites of disease,including supraglottic larynx and hypopharynx, present in the remaining patients.Nonmetastatic stage III or IV disease was present in approximately three-quartersof study patients. Reasons for ineligibility to receive cisplatin includedotopathology (69.0%), nephropathy (20.7%), and neuropathy (6.9%).

One-yearrates of PFS and OS for the overall study population were 76% and 86%,respectively. Furthermore, at a median follow-up of 21 months, the median PFShad not been reached and exceeded the hypothesized median PFS of 16 months,leading study authors to conclude that this approach deserves evaluation in arandomized trial.

Whilerespective 1-year PFS and OS rates were 88% and 94% for patients with p16/humanpapilloma virus (HPV)-positive cancers of the oropharynx, the correspondingrates were 58% and 75% for those with other type of LA-HNSCC.

Although the presence of programmed celldeath-ligand 1 (PD-L1)positive disease was not found to be associated withlikelihood of disease progression, the relative percentages of specific B-cellpopulations, such as a higher percentage of baseline naive B-cells and a lowerpercentage of marginal zone B cells, were associated with an increased risk ofprogressive disease.

Toxicitiesfrequently associated with administration of RT were observed, although grade 3or grade 4 lymphopenia was observed in over half of the study patients.

In their concluding remarks, the study authors stated that concurrent pembrolizumab and radiotherapy has demonstrated promising PFS and OS in LA-HNSCC, regardless of p16 status or anatomic location, with a favorable toxicity profile.

Disclosure: Some of the authors of theabstract disclosed financial relationships with pharmaceutical companies,medical device companies, and/or health-related companies. For a full list ofdisclosures, please refer to the abstract.

Reference

Weiss J, Vincent B, Deal A, et al. Progression-free survival, overall survival and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab. Presented at: Multidisciplinary Head and Neck Cancers Symposium; February 27-29, 2020; Scottsdale, AZ. Abstract LBA1.

See original here:
Promising Clinical Activity for RT Plus ICIs in Locally Advanced Head and Neck Cancers - Cancer Therapy Advisor

Read More...

‘Cotton ball’ sensation is a sign of neuropathy – Coastal Courier

Thursday, March 12th, 2020

DEAR DR. ROACH: Im a 63-year-old male diagnosed with chronic myelogenous leukemia, Type 2 diabetes and coronary heart disease. I am 5 feet, 11 inches and weigh 240 pounds. I have two stents and take Sprycel for the CML. My levels are good, and the coronary disease is under control.

For a few years Ive had what feels like cotton balls under the skin in the area of the balls of my feet. Now it feels like its migrating to the arch. While not too uncomfortable, it is almost impossible to walk barefooted. Some type of foot covering is needed to keep from noticing the feeling. My doctor says its the diabetes, and to lose weight or see a podiatrist. Other than losing the weight, do you have any opinion about this? N.M.

ANSWER: Cotton-ball sensation is one way that many people describe the beginning of neuropathy, a general term for a variety of different conditions that affect the nerves of the body.

In a person with cancer (like CML, chronic myelogenous leukemia, a cancer of the bone marrow) and a new symptom, it is always wise to consider whether it could be due to the cancer, the treatment for the cancer or from something else. In your case, usually CML is not associated with neuropathy. However, the medicine you are taking, dasatinib (Sprycel), has been associated with a severe kind of reversible neuropathy. I read the case reports of this condition carefully, and I doubt that is what is going on with you, as the symptoms you have are different from those reported.

People with longstanding diabetes frequently develop a particular disease of the nerves, diabetic neuropathy. This almost always begins with sensation changes in the feet. I agree with your doctor that diabetes is the most likely cause.

Seeing a podiatrist is absolutely a good idea. He or she can test you for this condition (usually a careful physical exam will make the diagnosis), in addition to looking carefully for any early signs or risk factors for injury or infection. You also should learn how to do a daily inspection of your feet and recognize the signs, so you can get to medical attention promptly should any damage to your feet occur. The podiatrist will make sure you have appropriate footwear.

Many people with diabetes benefit from weight loss, but the important thing is to be sure your diabetes is under good control. This is achieved through good diet, regular exercise and medication, if needed, in addition to weight loss in people who are overweight.

DEAR DR. ROACH: Due to cancer, my prostate was removed about seven years ago. My PSA reading has increased since 2012 from 0.09 to 0.304. Should I be concerned? I am 78 years old and in relatively good health. B.D.

ANSWER: PSA readings can go up and down, but a threefold increase could mean that the cancer is coming back, and you should see the specialist taking care of your prostate cancer to discuss getting additional testing.

Not having disease for seven years after treatment is a good sign, but the PSA test is pretty specific for cancer recurrence if two separate readings are above 0.2. You may need additional therapy, but only further investigation will show how concerned you need to be.

Dr. Roach regrets that he is unable to answer individual questions, but will incorporate them in the column whenever possible. Readers may email questions to ToYourGoodHealth@med.cornell.edu.

Go here to see the original:
'Cotton ball' sensation is a sign of neuropathy - Coastal Courier

Read More...

Breast Cancer Survivors Suffer Greater Loss of Well-Being than Noncancer Patients Later in Life – DocWire News

Thursday, March 12th, 2020

For breast cancer patients, the adverse effects of the cancer and its treatments do not cease when the disease leaves the body, and well-being remains affected. A new study found that older breast cancer survivors live with a higher level of actionable symptoms and greater loss of wellbeing over time compared to patients without cancer.

According to the authors, they undertook the study because there is little research regarding the long-term symptom burden carried by this population, as well as how this burden affects overall well-being and if lifestyle interventions influence it.

The study focused on breast cancer survivors aged 60 years with newly diagnosed, nonmetastatic breast cancer, who were compared to noncancer controls. Recruitment took place between August 2010 and June 2016. The following parameters were used to measure symptom burden: pain (yes or no), fatigue (on the Functional Assessment of Cancer Therapy [FACT]Fatigue scale), cognitive problems (on the FACTCognitive scale), sleep problems (yes or no), depression (on the Center for Epidemiologic Studies Depression scale), anxiety (on the StateTrait Anxiety Inventory), and cardiac problems and neuropathy (yes or no). A 100-point FACT-General scale was used to determine well-being. Lifestyle was assessed by factors including smoking, alcohol use, body mass index, physical activity, and leisure activities. Correlations were analyzed between treatment group (chemotherapy with or without hormone therapy, hormone therapy only, and controls) and symptom burden, lifestyle, and covariates; further analyses assessed how fluctuations in symptom burden and lifestyle affected function.

Symptoms were high at baseline across the whole cohort. The most significant differences between the cancer survivors and controls were observed in cognitive problems, sleep problems, anxiety, and neuropathy. In adjusted analyses, survivors who had undergone chemotherapy had the highest burden score, followed by those who had received hormone therapy, compared to controls (P<0.001). Factors that influenced the burden score were physical, emotional, and mental well-being; survivors with lower burden scores, compared to those with higher burden scores, had 12.4-point higher physical well-being scores. Lifestyle did not affect symptom burden or well-being, although physical activity played a large role in both (P<0.005).

The study was published in the March 15 issue of Cancer.

Cancer and its treatments are associated with a higher level of actionable symptoms and greater loss of wellbeing over time in older breast cancer survivors than in comparable noncancer populations, suggesting the need for surveillance and opportunities for intervention, summarized the study authors.

Read more from the original source:
Breast Cancer Survivors Suffer Greater Loss of Well-Being than Noncancer Patients Later in Life - DocWire News

Read More...

Neuropathy Pain Treatment Market by Companies, Regions, Type and Application 2026| Pfizer, Depomed, Eli Lilly – Weekly Wall

Thursday, March 12th, 2020

Los Angeles, United State The report titled Global Neuropathy Pain Treatment Market Research Report 2020 is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Neuropathy Pain Treatment market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Neuropathy Pain Treatment market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Neuropathy Pain Treatment market is carefully analyzed and researched about by the market analysts.

Global Neuropathy Pain Treatment Market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Top Key Players of the Global Neuropathy Pain Treatment Market: Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals,

Download Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart): https://www.qyresearch.com/sample-form/form/1436343/global-neuropathy-pain-treatment-market

The Essential Content Covered in the Global Neuropathy Pain Treatment Market Report:

* Top Key Company Profiles.

* Main Business and Rival Information

* SWOT Analysis and PESTEL Analysis

* Production, Sales, Revenue, Price and Gross Margin

* Market Share and Size

Global Neuropathy Pain Treatment Market Segmentation By Product:

Calcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthers

Global Neuropathy Pain Treatment Market Segmentation By Application:

Retail PharmaciesHospitalsOthers

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Neuropathy Pain Treatment Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Neuropathy Pain Treatment Market in South, America region is also expected to grow in near future.

Key questions answered in the report

* What will be the market size in terms of value and volume in the next five years?

* Which segment is currently leading the market?

* In which region will the market find its highest growth?

* Which players will take the lead in the market?

* What are the key drivers and restraints of the markets growth?

Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1436343/global-neuropathy-pain-treatment-market

Research Methodology

* Data triangulation and market breakdown

* Research assumptions Research data including primary and secondary data

* Primary data includes breakdown of primaries and key industry insights

* Secondary data includes key data from secondary sources

We provide detailed product mapping and analysis of various market scenarios. Our analysts are experts in providing in-depth analysis and breakdown of the business of key market leaders. We keep a close eye on recent developments and follow latest company news related to different players operating in the global Neuropathy Pain Treatment market. This helps us to deeply analyze companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study that will help you to stay on top of the competition.

About Us:

We established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Excerpt from:
Neuropathy Pain Treatment Market by Companies, Regions, Type and Application 2026| Pfizer, Depomed, Eli Lilly - Weekly Wall

Read More...

CarolinaEast oncology massage therapist followed calling [sponsored content] – New Bern Sun Journal

Thursday, March 12th, 2020

Patients undergoing chemotherapy or radiation therapy at the SECU Comprehensive Cancer Center at CarolinaEast Medical Center can receive three complimentary oncology massage treatments.

Arnie Smalldridge, a former administrative assistant at CarolinaEast, said she was inspired to pursue oncology massage therapy training after seeing how massaging her mother-in-laws feet helped to relieve cancer pain.

She also served as secretary to a patient and family advisory where she heard cancer patients talk about what helped to relieve them from pain.

While we were building the foundation of the cancer center, there were two patients who said massage was the only thing that helped them to handle their pain, Smalldridge said. I knew then that I wanted to go back to school. I was just blessed that CarolinaEast opened up this position for me.

Smalldridge graduated from a massage therapy program at Lenoir Community College in 2017, received an online certificate of completion for oncology massage and in May completed 32 hours of hands-on oncology massage therapy training in Raleigh.

It definitely was a calling, she said. Ive always believed strongly in the power behind the human touch. Sometimes I have patients in here and they live alone. They dont really have a caregiver. Just having someone to touch them and soothe them in that manner, thats all they need. Its psycho-social, if you will.

About five patients a day receive 45-minute treatments in her massage room at the cancer center. The low lighting, relaxing music and aroma therapy helps them to relax, she said.

I sit down with them first and talk with them about their condition to better know what I need to do for them, Smalldridge said. When you do oncology massage therapy, you have to be very mindful of your pressure with an oncology patient. If there is a tumor site, you have to avoid that.

She said oncology massage therapy is different from typical massage therapy in that the therapist must know where the cancer is in the patients body, the types of treatment they are undergoing and any side effects theyre experiencing.

You have to know if the cancer has spread, especially if it has metastasized into the bone marrow, Smalldridge said. The bones can be so fragile that you really want to watch your pressure in that area. You want to avoid any tumor sites. But you do want to focus on the tissue in those areas where the pain is and just do a very light treatment on them to try to release those tissues.

She said oncology massage therapy helps patients to relax and manage their pain better without the use of many pain medications.

It helps their sleep, improves immune function, Smalldridge said. They get peripheral neuropathy relief from massage and they get relief from nausea. They have so many side effects from their medications as far as joint pain, inflammation. Massage helps with that as well.

Therapy also helps with patients undergoing radiation treatments, she said.

The radiation treatment targets the tumor site, but it also irradiates tissues around that site, Smalldridge said. Breast cancer patients can end up with frozen shoulders. Humans guard themselves from pain. You see this in breast cancer patients. They throw their shoulders forward, which messes up their entire gait.

Some patients fear the pain they feel means the cancer has spread or metastasized, she said.

What I do is I help them to understand that these are side effects, that its not a metastasized site, Smalldridge said.

She usually sees patients who are in treatment for cancer, but doctors have referred some patients to her who are three to five years out of treatment.

What I have seen there is that even in their survivor state, three to five years later, theyre still showing effects of the chemo treatment or the radiation treatment, Smalldridge said. They have to get used to the new normal.

Read the original:
CarolinaEast oncology massage therapist followed calling [sponsored content] - New Bern Sun Journal

Read More...

Be Strong and Proud on Rare Disease Day – Pain News Network

Sunday, March 1st, 2020

The National Institutes of Health is coordinating panel discussions on Friday, February 28 in Bethesda, MD to improve diagnosis and treatment, expand clinical trial resources, and increase awareness of rare diseases.

In all, NORD lists over 400 events in 106 countries marking Rare Disease Day, including conferences, research presentations, exhibits, walks, rallies and a variety of fundraisers.

Rare Disease Day started in 2008 with the first events held in Canada and Europe. The date February 29 was chosen because it is rare (Rare Disease Day is on February 28 in non-leap years).

Rare diseases and disorders often go undiagnosed and untreated. Due to their rarity, expertise, treatment and resources are limited for people living with a rare disease, who can also face discrimination at work and school.

Research on rare diseases can actually help improve understanding of more common disorders and lead to new treatments. For instance, Yale neuroscientist Dr. Stephen Waxman discovered the gene SCN9A and its role in two painful hereditary neuropathies. Treatments for these disorders may help people with many other forms of peripheral neuropathy, as Waxman explains in his book, Chasing Men on Fire.

Moreover, rare diseases are often misunderstood. They do not look like typical illness and may require unusual forms of medical care. So Rare Disease Day also represents a chance to raise awareness about the importance of research, specialist centers, and healthcare professionals who work on such disorders.

Although most rare diseases do not have a cure, they can all be managed and patient lives improved. Rare Disease Day is an opportunity to focus on promising research, improving patients lives, and promoting action.

Roger Chriss lives with Ehlers Danlos syndrome and is a proud member of the Ehlers-Danlos Society. Roger is a technical consultant in Washington state, where he specializes in mathematics and research.

Here is the original post:
Be Strong and Proud on Rare Disease Day - Pain News Network

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Swot (Strengths, Weaknesses, Opportunities, And Threats) analysis By…

Saturday, February 29th, 2020

Chemotherapy Induced Peripheral Neuropathy Treatment market Research Report 2020 offers a comprehensive analysis of the market growth drivers, trends, opportunities, prospects, drivers and restrictions inside the market. The report emphasizes to meet the requirement of customers by providing complete knowledge of the Chemotherapy Induced Peripheral Neuropathy Treatment Industry. This carefully organised report is formulated by industry experts and professional experts, in terms of demand and supply, cost organization, barriers and challenges, product category, crucial market players, technology, regions, and applications.

The Chemotherapy Induced Peripheral Neuropathy Treatment market study is based on historical information and present market requirements. As well as includes different business approaches preferred by the decision-makers. That enhanced the Chemotherapy Induced Peripheral Neuropathy Treatment industry growth and make a phenomenal stand in the industry. The market will raise with a prominentCAGRby 2020 to 2025.

Download Free Sample Report

https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368 #request_sample

Furthermore, it also evaluates the most recent improvements while estimating the growth of theleading playerslike

Aptinyx Inc, Sova Pharmaceuticals Inc, MAKScientific LLC, Asahi Kasei Pharma Corp, PledPharma, Regenacy Pharmaceuticals, Immune Pharmaceuticals Inc, Nemus Bioscience Inc, Metys Pharmaceuticals AG, DermaXon LLC, WinSanTor, Kineta Inc, Solasia Pharma K.K., Apexian Pharma, Krenitsky Pharmaceuticals Inc, PeriphaGen,

Segmentation by Product Type

By TypeChemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others, etc.

Segmentation by Application/ End uses:

By Application Chemotherapy Induced Peripheral Neuropathy Treatment has been segmented into Platinum Agents, Taxanes, Vinca Alkaloids, Others, etc.

Regional Analysis for Chemotherapy Induced Peripheral Neuropathy Treatment Market:

North America (the United States, Canada & Rest of the countries)

Europe (Germany, The UK, France, Netherlands, Italy, Spain & the rest of the countries)

Asia-Pacific (China, Japan, Korea, India, & rest of the countries)

Middle East & Africa (South Africa, Israel, UAE & rest of the countries)

South America (Brazil, Colombia, Argentina & the rest of the countries)

Ask For discount

https://www.reportspedia.com/discount_inquiry/discount/49368>

What is the regional structure of the market? Our analysis-

The Chemotherapy Induced Peripheral Neuropathy Treatment Industry report analyses footprint of every product and its significance analyzes examine each geographical segment of the market with import, export, consumption, and production in these regions to provide a complete understanding of the Chemotherapy Induced Peripheral Neuropathy Treatment market

In addition, the Chemotherapy Induced Peripheral Neuropathy Treatment Industry report covers an analysis of different products available in the global market built on production, volume, revenue, and cost and price structure. The Chemotherapy Induced Peripheral Neuropathy Treatment Market report also highlights key strategies that proved to be profitable for the business in-line with the policies involved in business expansion, partnership deals, composition, and new product/service launches.

YEARS CONSIDERED FOR THIS REPORT:

Historical Years:2015-2019

Base Year:2019

Estimated Year:2020

Forecast Period:2020-2025

DEFINITE SEGMENTS OF GLOBAL Chemotherapy Induced Peripheral Neuropathy Treatment INDUSTRY:

The analysis highlights a region-wise as well as a worldwide study of the Chemotherapy Induced Peripheral Neuropathy Treatment market. Proportionately, the regional study of the industry comprisesJapan, South East Asia, India, the USA, Europe, and China.Moreover, the report reviews an in-depth market analysis of distinct manufacturers and suppliers. It explainsindustry chain structure, competitive scenario, and study of Chemotherapy Induced Peripheral Neuropathy Treatment industry costin detail. It evenly analyzes global industry size pursued by forecast period (2020-2025) and environment.

Ask For Report Customization

https://www.reportspedia.com/inquiry/customization/49368

The analysis covers basic information about the Chemotherapy Induced Peripheral Neuropathy Treatment product likeindustry scope, segmentation, anoverviewof the market. Likewise, it providessupply-demand data, investment feasibleness, and elements that limiting the growth of an industry. Predominantly, it helps product demand, annual revenue and growth prospects of the industry. The foreseen Chemotherapy Induced Peripheral Neuropathy Treatment market regions along with the present onesassist leading vendors, decision-makers, and viewers/readersto plan effective business strategies respectively.

KEY TOPIC COVERED

Growth Opportunities

Market Growth Drivers

Leading Market Players

Market Size and Growth Rate

Market Trend and Technological

Company Market Share

TOC OF Chemotherapy Induced Peripheral Neuropathy Treatment MARKET REPORT INCLUDES:

1 Industry Overview of Chemotherapy Induced Peripheral Neuropathy Treatment

2 Industry Chain Analysis

3 Manufacturing Technology

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment by Regions, Creators, Types, and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate by 2013-2019

7 Consumption Volumes, Consumption Value, Import, Export and Sale Price Analysis by Regions

8 Gross and Gross Margin Analysis

9 Marketing Traders or Distributor Analysis

10 Global and Chinese Economic Impacts on the Chemotherapy Induced Peripheral Neuropathy Treatment Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry 2019 Market Research Report Continued

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Key questions answered by the Chemotherapy Induced Peripheral Neuropathy Treatment Report:

What are some of the most favourable, high-growth prospects for the global Chemotherapy Induced Peripheral Neuropathy Treatment market?

Which products segments will raise at a faster pace throughout the forecast period and why?

What are the foremost factors impacting market prospects?

What are the driving factors, restraints, and challenges in this Chemotherapy Induced Peripheral Neuropathy Treatment market?

What are the competitive threats and challenges to themarket?

What are the evolving trends in this Chemotherapy Induced Peripheral Neuropathy Treatment market and reasons behind their emergence?

What are some of the changing customer demands in the Chemotherapy Induced Peripheral Neuropathy Treatment Industry market?

Continue

Explore More Information

https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368 #table_of_contents

See original here:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Swot (Strengths, Weaknesses, Opportunities, And Threats) analysis By...

Read More...

Possible Associations of Vitamin D, Vitamin D-Binding Protein, and Vit | JPR – Dove Medical Press

Saturday, February 29th, 2020

Asuman Celikbilek

Department of Neurology, Kudret International Hospital, Ankara, Turkey

Correspondence: Asuman CelikbilekKudret International Hospital, Department of Neurology, Ankara 06600, TurkeyTel +90 505 6532615Fax +90 312 229 98 68Email asunebioglu@yahoo.com

We read with great interest the article recently published in Journal of Pain Research by Sari et al,1 examining the effect of vitamin D replacement therapy on neuropathic pain and imbalance in patients with diabetic neuropathy (DN). They found that vitamin D replacement reduced neuropathic pain and improved balance scores in patients with DN. They suggested that a vitamin D replacement schedule might be planned in diabetic patients with vitamin D deficiency in order to resolve neuropathic pain and balance problems. However, we would like to add some points which may be taken into consideration.

View the original paper by Sari and colleagues

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Possible Associations of Vitamin D, Vitamin D-Binding Protein, and Vit | JPR - Dove Medical Press

Read More...

Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates – BioSpace

Saturday, February 29th, 2020

XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Womens Cancer

XMT-1536 interim Phase 1 dose expansion data to be presented in 2Q 2020 with more mature data expected in 2H 2020

Company to present preclinical data on ADCs created with the Dolasynthen and Immunosynthen platforms at the American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2019.

We are excited to present updated data from our ongoing dose escalation study in heavily pre-treated and biomarker unselected patients at the upcoming SGO 2020 Annual Meeting on Womens Cancer. We plan to demonstrate that, at doses up to 43 mg/m2, XMT-1536 is well tolerated without the severe neutropenia, neuropathy or ocular toxicities typically observed with other ADC platforms, said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. Additionally, we continue to execute on our proof-of-concept expansion cohorts in ovarian and non-small cell lung cancer for XMT-1536 and are on track for additional data disclosures throughout the year. These data readouts will be important milestones as we chart a fast-to-market path to registration in ovarian cancer.

Recent Highlights and Updates

Clinical Programs

Discovery & Platform Progress

Upcoming First Quarter 2020 Events

2019 Financial Results

Cash, cash equivalents and marketable securities as of December 31, 2019, were $99.8 million, compared to $70.1 million as of December 31, 2018. In addition, the Company has the option to draw additional funds of up to $15.0 million through the existing debt financing agreement with Silicon Valley Bank. The Company expects that its current cash, cash equivalents and marketable securities will enable it to fund its operating plan through important milestones, including the XMT-1536 Phase 1 clinical study and the planned dose escalation study for XMT-1592.

Fourth Quarter 2019

Full Year 2019

Conference Call DetailsMersana Therapeutics will host a conference call and webcast today at 8:00 a.m. ET to report financial results for the fourth quarter and year-end of 2019 and provide certain business updates. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 4849085. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at http://www.mersana.com.

About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. Mersanas second product candidate targeting NaPi2b-expressing tumors, XMT-1592, is an ADC created using Mersanas customizable and homogenous Dolasynthen platform. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on managements beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Companys business strategy and the design, progression and timing of its clinical trials. Forward-looking statements generally can be identified by terms such as anticipates, believes, could, seeks, estimates, intends, may, plans, potential, predicts, projects, should, will, would or similar expressions and the negatives of those terms. Forward-looking statements represent managements beliefs and assumptions only as of the date of this press release. The Companys operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Companys results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials, that the development and testing of the Companys product candidates and new platforms will take longer and/or cost more than planned and that the identification of new product candidates will take longer than planned, as well as those listed in the Companys Annual Report on Form 10-K filed on February 28, 2020, with the Securities and Exchange Commission (SEC) and subsequent SEC filings. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Mersana Therapeutics, Inc.Selected Condensed Consolidated Balance Sheet Data(in thousands)(unaudited)

Mersana Therapeutics, Inc.Condensed Consolidated Statement of Operations(in thousands, except share and per share data)(unaudited)

Contact:

Investor & Media ContactSarah Carmody, 617-844-8577scarmody@mersana.com

Read the original here:
Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates - BioSpace

Read More...

Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management – Zionsville…

Saturday, February 29th, 2020

February 2020

Are you looking for a health care provider who offers innovative alternatives and a customized approach to your health issues? Indiana Regenerative Medicine Institute (IRMI) believes in offering specialized alternatives to health care. Its medical team, headed by Doctor of Chiropractic Preston Peachee, utilizes the latest developments in regenerative medicine, hormone replacement and pain management.

Dr. Peachee is a native of Jasper, Indiana. He graduatedfrom Logan College of Chiropractic and has been in practice since 2003. Hisareas of specialty include patients with chronic and severe back, neck andjoint pain as well as other complex neurological conditions.

Dr. Peachee has earned a reputation as an innovative thinkeras well as a compassionate practitioner who brings his wide expertise andexperience to the Greater Indianapolis area. His ability to help those in needof regenerative medicine, neuropathy pain relief, low testosterone or otherphysical ailments, such as back pain or fibromyalgia, makes him not only uniquebut highly sought-after.

A key member of the IRMI team is Leann Emery, FNP. Emery isa family nurse practitioner with more than 20 years of experience in hormonereplacement and alternative pain management. Emery provides optimal patientcare through personal consultations and assessments to identify her patientsspecific health needs. She was rated in the top 10% of providers in the U.S.with patient satisfaction.

Regenerative medicine is making huge leaps in our understanding of the human body, and it is offering real, possible treatments that would have seemed like science fiction a few short years ago, according to IRMI. Most patients we see have tried other more traditional treatments and have either not gotten any better or have gotten even worse. Unfortunately, a lot of people we see depend on multiple medications per day to try and function but still are not happy with how they feel or how they live their lives. It is unfortunately the nature of deteriorating and degenerative joints, they will get worse with time, and generally the pain increases as well.

Depending on the injury, Dr. Peachee will often combinelaser therapy with the regenerative medicine protocols to improve the outcomesand try and speed the recovery process.

We offer mesenchymal stem cell therapy, Dr. Peachee said. With the combination of laser therapy, mesenchymal stem cell therapy is incredibly effective for rotator cuff problems and treating knee pain. Eighty percent of our stem patients are dealing with knee pain or Osteoarthritis. Osteoarthritis-or O.A. of the knee- is a huge problem for a lot of people, and we get great results from these therapies. Most people can even avoidknee surgery.

Dr. Peachee recently introduced hormone treatments for low testosterone. Family Nurse Practitioner Leann Emery has been doing [hormone] treatments for 20 years, and that area of medicine became a natural fit for IRMI.

I have several patients who were seeking this type ofcaremany who are police officers and firefighterswho couldnt find thetherapy and individualized care and attention that they needed.

Dr. Peachee explained that low T treatments help patients with unique and even complicated cases of Erectile Dysfunction (E.D.). Most people seek us out for treatment because they are tired, worn out, stressed out and just simply lack the energy they used to have.

We are able to fill a niche with patients who hadcomplicated cases that were not responding well with their primary careproviders or other places, Dr. Peachee shared. We have a patient who hasstruggled for a long time with fertility issues but has done very well [withtreatments], and we just got good news that he and his wife are expecting aftertrying for a really long time. So, he is really enthused about that.

The typical candidates for low T treatments, according toDr. Peachee, are men who feel worn out, are lethargic and have lost theirzest for life.

Our patients dont have the same pep that they had 10 or20 years ago, Dr. Peachee stated. They struggle getting up in the morning andmight be struggling in the afternoon after having six cups of coffee or threeRed Bulls just to get through the day. We have a lot of people that want to getback into the gym and get the maximum benefit of their workouts. We can helpthem improve their overall health and energy so that they can enjoyrecreational activities like working out or practice with the Little Leaguewith their kids. Many times we hear from spouses, friends and family how muchbetter they feel and that they seem happier and get more out of life again.

It goes without saying that proper hormonal balance canimprove a patients personal relationships as well and improve the overallmental health of a patient by reducing stress, anxiety and depression oftencaused by symptoms related to low testosterone levels.

We focus on injectable [low T] treatments because we canmodify the dosage and give more frequent doses to keep our patients at a levelthats going to give them the maximum benefit and improvement for theirconditions, Dr. Peachee explained.

With the modern changes in medicine over the last 20 and 50years, were helping people to live a lot longer and adding 20 to 30 years totheir lives, but we have not given them an improved quality of life as theyage. By working with their hormones and getting them in balance, their qualityof life becomes way better, and were seeing a positive improvement for manypeople with these treatments.

Patients suffering from severe disc injuries, such a bulgingor herniated disc or discs, or who suffer from degenerative disc disease mayhave undergone treatment from chiropractors or have seen physical therapistsbefore coming to Indiana Regenerative Medicine Institute.

Our typical patient who comes in for this type of treatmenthas seen other therapists or chiropractors but hasnt found lasting relief,Dr. Peachee said. Many of our patients want to get off the rollercoaster ofopioids and pain medications. They are looking for a solution without narcoticsand risk of addiction or other possible negative side effects of narcoticsand/or surgery. We are generally able to alleviate the pain in 90% of patientsand are able to keep them from having surgery or from taking addictivemedications.

Laser therapy allows Dr. Peachee to work on the damaged tissue so that it can heal, and the method reduces inflammation and swelling in a way that traditional treatments cannot.

Its an innovative new therapy within the last decade thatallows us to do some amazing things, Dr. Peachee stated. We perform ourprocedures in our office and have several different devices for the specificneeds and issues of our patients. For instance, we have a unique device forpeople with knee pain that can help the majority of our patients walk betterand live more pain-free. We get a phenomenal outcome with this procedure.

One of the other major differentiators that sets IndianaRegenerative Medicine Institute apart from other offices and clinics is thatthey are advocates for their patients, especially when it comes to dealing withtheir patients insurance providers.

A lot of our low T patients are able to get their insurancecarriers to cover the services so that it doesnt cost them as much out ofpocket for the care they seek, Dr. Peachee said. Weve partnered with abilling company that has helped us to be able to navigate the craziness of ourmodern insurance companies, and by doing so, were able to keep the cost downfor a lot of patients. Not every insurance plan will cover this type of care,but a lot of them will. When its possible and ethical, we do whatever we canto benefit our patients to help keep the cost low. I have spent a lot of freetime writing letters on behalf of our patients. We go above and beyond with ourservice and care of our patients.

The Indiana Regenerative Medicine Institute team will make housecalls or come to a patients place of work when the situation calls for thatlevel of care.

We will go and draw blood for blood work, bring medications and even do exams in some situations, Dr. Peachee said. As I mentioned before, we see a lot of police officers and firemen all over the statefrom Mishawaka to South Bend and all over Indiana. We go once a month to see these patients at their departments and stations so that we see them all in one day versus making 10 to 15 guys drive hours to come in to see us. Its a service we can offer because we are a small clinic and we are focused on that one-on-one patient attention and relationship building. We have great relationships with our patients, and thats something that we work very hard at.

Building trust and transparency is crucial to the success ofhis practice, Dr. Peachee emphasized. The trust that we build with ourpatients is crucial to not only the success of the practice but to thepatients outcomes. And not just with hormone therapy but also with ournonsurgical spinal decompression patients. These are patients with significant discinjuries, and we need them to tell us everything we need to know so we can givemore accurate and complete care for a better outcome.

I would say to anybody if you have any doubts or reservations to take some of the burden and some of the anxiety out of the equation and schedule an initial consultationabsolutely free of charge, Dr. Peachee encouraged.

Dont put off living your best life any longer. Visit Indiana Regenerative Medicine Institutes website at indianaregen.com or call (317) 653-4503 for more information about its services and specialized treatments and schedule your free consultationtoday!

Writer:

Janelle Morrison

Photography:

Laura Arick and submitted

Read more:
Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management - Zionsville...

Read More...

Page 16«..10..15161718..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick